PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10

作者：

Xiao, Jun ^{[1
]}

Deng, Yi-Min ^{[1
]}

Liu, Xiang-Rui ^{[1
]}

Cao, Jian-Ping ^{[2
]}

Zhou, Min ^{[1
]}

Tang, Ya-Ling ^{[1
]}

Xiong, Wen-Hao ^{[1
]}

Jiang, Zhi-Sheng ^{[1
]}

Tang, Zhi-Han ^{[1
]}

Liu, Lu-Shan ^{[1
]}

机构：

[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China

[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China

来源：

CLINICA CHIMICA ACTA | 2019年 / 495卷

基金：

中国国家自然科学基金;

关键词：

Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;

D O I：

10.1016/j.cca.2019.05.005

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.

引用

页码：358 / 364

页数：7